Information Provided By:
Fly News Breaks for February 27, 2020
XLRN
Feb 27, 2020 | 07:27 EDT
Barclays analyst Carter Gould initiated coverage of Acceleron with an Overweight rating and $107 price target. He sees Reblozyl as a "blockbuster in the process of launching" and notes that a second wholly-owned asset, sotatercept, has been meaningfully de-risked and is potentially complementary to all other therapies in pulmonary hypertension, which he estimates as a $5B-$6B space. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations.
News For XLRN From the Last 2 Days
There are no results for your query XLRN